Use of Donanemab in Early Symptomatic Alzheimer Disease / Reply

Pomara and Imbimbo comment on the study on the use of donanemab in early symptomatic Alzheimer disease. The TRAILBLAZER-ALZ 2 trial 1 provided additional evidence that the APOE4 genotype is a risk factor for amyloid-related imaging abnormalities, especially cerebral edema and effusion. These finding...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2023-12, Vol.330 (23), p.2304
Hauptverfasser:	Pomara, Nunzio, Imbimbo, Bruno Pietro, Evans, Cynthia D, Sims, John R
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Alzheimer's disease Apolipoprotein E Blood-brain barrier Central nervous system Cerebrospinal fluid Clinical trials Edema Effusion Genotypes Medical imaging Monoclonal antibodies Neurodegenerative diseases Neuroimaging Risk factors β-Amyloid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!